



Innovative Lab Tests for Cancers & Chronic Diseases

NASDAQ: AIDX

Virtual Investor Webinar

February 26, 2026



Forward Looking Statements

This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the Company's actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and the Company is under no duty to update any such statements to conform them to actual results.

In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. If our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements.

This presentation does not constitute an offer to sell or an invitation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment, whatsoever. Specifically, these materials do not constitute a "prospectus" within the meaning of the US Securities Act of 1933, as amended, and the regulations enacted thereunder. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Any decision to purchase the Company's securities should be made solely on the basis of the information contained in the Company's public filings. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offence.

THE INFORMATION CONTAINED IN THIS DOCUMENT IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER.

Presentation Agenda

- **About 20/20 Biolabs (Nasdaq: AIDX)**
- **Four Recent Macro-Developments that Might Help Accelerate AIDX in 2026 and Beyond**
 - 1) New law passed by Congress to enable Faster Medicare Coverage for MCEDs (Feb. 2026)
 - 2) New CMS program to pilot Medicare Solutions that help Improve Diet & Lifestyle (Dec. 2025)
 - 3) Acquisition of EXAS by Abbott (Dec. 2025)
 - 4) Release for Grail *Galleri* NHS Clinical Trial Data (Feb. 2026)
- **Transfer of 20/20 Shares to Brokerage Accounts**
- **Q&A**

Company Overview

20/20 Biolabs is a commercial stage clinical laboratory test developer focused on AI powered blood tests for the early detection and prevention of cancer and chronic diseases.

- **Newly Public Listing – NASDAQ: AIDX**
- **OneTest™ for Multiple Cancers** is seeing rapid adoption for Multi-Cancer Early Detection (MCED)
- Early detection saves lives in **fast growing MCED Market.**
- **Feb. 2026 law passed by Congress provides a pathway for Medicare reimbursement for MCEDs by 2028**
- **Year-over-year revenue growth and line-of-sight to profitability** in markets including Firefighting, Veterans, Occupational Health & Self-Insured Employers
- Launched a companion **Longevity Blood Test** targeting consumers interested in wellness, healthy aging, inflammation and chronic disease
- **Partnership with Giant Foods**, largest supermarket chain in Washington, D.C. region
- Sustainable competitive advantages protected through unique data sets & patents



Multi-Cancer Test


Market Opportunity

- Few practical screening options for lung, pancreatic, ovarian, liver, and other deadly cancers despite evidence that **early detection saves lives**
- New Multi-Cancer Early Detection (MCED) blood tests aim to fill this void, but most suffer from these **limitations**:
 - Too **expensive**. Avg. \$800 per test
 - Fail to detect most **early-stage cancers**
 - Require painful and inconvenient **venipuncture** using only trained phlebotomists



US Multi Cancer Early Detection Market Size¹

\$ in Millions



This surge is being driven by:

- Rising cancer incidence and demand for early, non-invasive diagnostic tests
- Ease of access with at-home collection devices
- Increasing public awareness and healthcare system adoption
- Moderate regulatory oversight of laboratory developed tests (LDTs) by CLIA not FDA
- **New law passed by Congress (bipartisan) in Feb. '26 creates pathway for Medicare reimbursement of MCEDs by '28**

OneTest™ for Cancer

Solution & Competitive Advantages

The **first and only MCED** available in the U.S. that:

- Starts at **under \$200**
- Can be **accessed at home** without painful needles
- Has been demonstrated to identify many cancer types **at earlier stages than competing ctDNA based MCEs**
 - Includes those of the lung, pancreas, and ovaries that when detected at an earlier stage can usually be more effectively treated



**NATIONAL
CANCER
INSTITUTE**



About OneTest™

- Measures a panel of **tumor antigens** (CEA, AFP, CA-19.9, CA-125, Ca-15.3, Cyfra, PSA) plus **inflammatory markers** (in OneTest Premium)
- Biomarker tests are common for cancer screening in **East Asia**
- **Strong patent position** covering screening w/ machine learning + tumor antigens
- Useful in early detection of multiple deadly types of cancer (lung, liver, pancreas, etc.)
- Utilizes FDA approved instruments and kits (immunoassay)
- **Powered by machine learning algorithm** built with outcome data from over 40,000 previously tested individuals
 - **AI powered algorithms proven to substantially boost test performance**
- CLIA Certified, CAP Accredited, High Complexity Laboratory
- Over 25,000 tests sold to date




onetestforcancer.com

CLIA
Certified

CAP
ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Better Accuracy for Earlier Stage Cancers

- Data from multiple, independent sources suggests that **MCEDs based on proteins tend to be more sensitive** (i.e., miss fewer true cancers) especially for **early-stage tumors** than those based on circulating tumor DNA¹
- MD Anderson Cancer Center found that **tumor antigens outperformed ctDNA** for lung and pancreatic cancers
- OneTest Premium was recently validated in a blinded study in conjunction with the NIH, where it performed exceptionally well²
- Ongoing prospective studies of Grail's Galleri test ("Pathfinder") indicate that **ctDNA misses more stage 1 and 2 cancer than 20/20's OneTest³**



¹Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. *Diagnostics*, 11(12), 2171. [Exploring Circulating Tumor DNA \(CtDNA\) and Its Role in Early Detection of Cancer: A Systematic Review](#). *Cureus*, 15(9), e45784 (2023).

²OneTest™ Premium: Demonstrating early detection of cancer with PLCO samples. *14th EDRN Scientific Workshop, Gaithersburg, MD, May 2025*.

³Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Annals of oncology : official journal of the European Society for Medical Oncology*, 32(9), 1167–1177 (2021). (2023). [Blood-based tests for multicancer early detection \(PATHFINDER\): a prospective cohort study](#). *Lancet (London, England)*, 402(10409), 1251–1260.(2023)

Customer: Fire Departments

- 200+ Fire Departments current customers (w/ ~3 new Departments each month)
 - Implemented into routine physicals
- Thousands of firefighters
 - Largest department over 1,400 screened
- Many repeat customers
 - Yearly screening programs
- Revenues increasing year over year even before state grants become available
- **The total number of active and retired firefighters (career & volunteer) in the U.S. is estimated to exceed 2 million**



State Funding for Firefighter Cancer Screening Programs

- **New Jersey** - \$1,250 for career FF
- **Oklahoma** - \$6M
- **Maryland** recently increased to \$1M
- **New Hampshire** – applications under review for \$5M funded testing
- **Vermont** – 1000+
- **Louisiana** – required screenings
- FEMA Assistance to Firefighter Grant (AFG) program plus County and Municipal appropriations are also used for cancer screening

State of New Jersey, Department of the Treasury, Division of Administration. "[Firefighter Cancer Screening Reimbursement Program.](#)" *NJ.gov*, 24 Mar. 2025.

Stecklein, Janelle. "[House Committee Advances Measure That Would Provide Free Cancer Screenings for Oklahoma Firefighters.](#)" *Oklahoma Voice*, 12 Feb. 2024.

SB 578 – Fiscal and Policy Note from the Maryland General Assembly website

"[State OKs \\$5M Funding Program for Firefighter Cancer Screenings.](#)" *The Rochester Voice*, 25 Dec. 2025

"LA Firefighters to Receive Free Cancer Screenings Under New Law." *Firefighter Nation*, 20 Dec. 2024, www.firefighternation.com.

Customer: **Veterans**

- Post 9/11 veterans have an increased risk for cancer (chemicals; burn pits)
- Non-profit organization, The HunterSeven Foundation, transitioned from Grail's Galleri to OneTest for Cancer
- Tested ~800 veterans in 2025 and **helped identify at least 20 early-stage cancers**
- About 4 million veterans served in either Iraq or Afghanistan



Firefighters & Veterans = \$1 Billion Market
for Multi-Cancer Screening
w/ Sustained Reimbursement (Federal & State)

**We Believe 20/20 is the current
market leader in MCED testing in both
markets**

6,000,000 x \$170 ASP =
\$1.02 Billion per year market

OneTest for Longevity–New Product


Biomarker Tracking for Healthy Aging

- Targeting consumers interested in wellness, healthy aging, inflammation and chronic disease
- **Competitive Advantage:** Tracking of biomarkers together with dietary patterns (through the Dietary Inflammatory Index™)
- **Launched in February 2026**
- Subscription packages starting at **\$39 per month:**
 - Quarterly testing to track inflammatory biomarkers over time
 - Capillary blood collection at Workplaces, Med Spas, Health Clubs, Supermarkets or at home (avoiding need for phlebotomists)
 - Customized dietary recommendations using the *Dietary Inflammatory Index™ (DII™)* scoring system
 - Optional purchase of anti-inflammatory meals



OneTest for Longevity Rollout

- **Expanding sales & marketing teams** with additional account managers and prospecting reps
- **Overlap with many MCED customers**
- **Robust opportunity for D2C**
 - Subscription model
- **New Targets**
 - Self-insured employers
 - GLP-1 patients
 - Supermarkets—tied to *Food as Medicine*



Customer: Occupational Health & Self-Insured Employers

20+ Occupational Health Partners

- One-to-Many Approach
- Each services several fire departments and other occupations
- Include OneTest in yearly physicals
- Market on our behalf
- Early adopters for additional products

Self-Insured Employers

- Promising market with increasing interest
- Innovative Health Benefits
 - Workplace Health Initiatives
 - Productivity
 - Cost Savings
 - Talent Attraction & Retention
- Early adopters currently running first tests
- In discussions with large potential customers



- More direct, near-term return on investment (ROI) for employers and employees
 - Reduce health insurance claims
 - Reduce absenteeism
 - Enhance workforce productivity for participating employees
 - = **350% return on investment** within 12-18 months of adoption of testing

Partnership with Giant Foods

- Ahold Delhaize USA operating major grocery brands including Giant Food (163 supermarkets in the Washington, D.C. region), Food Lion, The GIANT Company, Hannaford, and Stop & Shop, serving millions weekly
- Successful 2025 Pilot program at nine Giant stores providing customers with early access to OneTest for Cancer @ store pharmacies
- In discussions to offer Longevity test at Giant stores in 2026 linked to digital coupons for healthy, anti-inflammatory, grocery items
- Builds on parent company Ahold Delhaize banner's ongoing efforts to provide shoppers with preventative health resources



OneTest for Longevity Benefits to Americans on Ozempic and other GLP-1 Drugs

- GLP-1 use reduces inflammatory biomarkers such as C-reactive protein (CRP), TNF- α , and IL-6 during GLP-1 therapy
- These biomarker levels help signal cardiovascular risk, metabolic disease, immune function, and biological aging, top of mind for many GLP-1 users
- Users of these medications are being encouraged to monitor inflammatory biomarkers to track health benefits beyond weight loss

GLP-1s Are Becoming Long-Term Lifestyle Medications, rapidly evolving from short-term weight-loss tools into long-term chronic therapies used by millions of Americans

- Large, fast-growing addressable market of GLP-1 users
- Strong consumer willingness to pay monthly for monitoring
- Natural integration with dietary, lifestyle, and “food as medicine” strategies already embedded in OneTest for Longevity

OneTest for Longevity is positioned to become a go-to monitoring tool for the GLP-1 era of preventive and longevity-focused medicine.



Healthy Food Coupons as Additional Recurring Revenue Streams

Many diagnostic testing labs sell nutritional supplements or personalized nutrition products linked to biomarker levels- (“precision health”) tying lab results to lifestyle or supplement recommendations. Examples:

- **TruDiagnostic (TruHealth):** Offers biomarker testing for 100+ markers (vitamins, antioxidants, fats, amino acids, toxins) and pairs results with personalized supplement recommendations.
- **Function Health:** Partners with Quest Diagnostics to deliver 100+ lab tests, then provides lifestyle and supplement guidance based on results.
- **Superpower:** Uses biomarker testing as the foundation of its supplement and lifestyle programs, emphasizing personalized interventions.

Most supplements lack solid evidence of safety and efficacy.

We intend to be among the first diagnostic labs to promote healthy whole foods that positively impact biomarker levels.



Pioneering Dx w/ AI for over 10 Years



Article

Improving Multi-Tumor Biomarker Health Check-Up Tests with Machine Learning Algorithms

Hsin-Yao Wang^{1,2,3}, Chun-Hsien Chen^{1,4}, Steve Shi², Chia-Ru Chung⁵, Ying-Hao Wen¹, Min-Hsien Wu⁶, Michael S. Lebowitz², Jiming Zhou^{2,*} and Jang-Jih Lu^{1,2,7,8,*}

- Department of Laboratory Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, Taiwan; mdhsinyawang@gmail.com (H.-Y.W.); cchen@mail.cgu.edu.tw (C.-H.C.); b9209011@cloud.cgmh.org.tw (Y.-H.W.)
- 20/20 GeneSystems, Inc., Rockville, MD 20850, USA; peichang@2020gene.com (S.S.); mlebowitz@2020gene.com (M.S.L.)
- Program in Biomedical Engineering, Chang Gung University, Taoyuan City 33301, Taiwan
- Department of Information Management, Chang Gung University, Taoyuan City 33301, Taiwan
- Department of Computer Science and Information Engineering, National Central University, Taoyuan City 32001, Taiwan; jjrchris@g.ncu.edu.tw
- Graduate Institute of Biomedical Engineering, Chmhwu@mail.cgu.edu.tw
- Department of Medical Biotechnology and Labora Taoyuan City 33301, Taiwan
- Department of Medicine, College of Medicine, Ch
- * Correspondence: jzhou@2020gene.com (J.Z.); jang +886-3-211-8800 (ext. 5816) (J.-J.L.); Fax: +240-403-

Received: 23 April 2020; Accepted: 29 May 2020; Publ

From: Allen, Steven P
 To: Jiming Zhou
 Cc: Howell, Renee; Pamela Banning; Michelle McLean; Wang, Young; David Luta
 Subject: AACC Annual Meeting Poster Competition
 Date: Monday, August 2, 2021 3:52:59 PM

Hello Jiming,

On behalf of the AACC Industry Board, I would like to congratulate you on your poster "Algorithms Developed using Long Short-term Memory Machine Learning Models Can Appreciably Improve Cancer Screening with Tumor Biomarkers" being selected as the Industry Division's 1st Place poster winner.

I will be following up in the near future with more details regarding your first place finish. The Industry Board would also like you to present your work in an upcoming Webinar, day and time to be worked out in the future.

Again, congratulations,
 Steven P. Allen, Chair, AACC Industry Division

Abbott Steven P. Allen, Ph.D. Abbott O: +1 224-668-1006
 Mgr. Biologics Process Design & Analytical Chemistry 100 Abbott Park Rd. M: 224-234-9097
 Volviler Research Fellow Dept. 09NC, Bldg. AP20 steven.allen@abbott.com
 Abbott Diagnostics Division Abbott Park, IL 60064



ELSEVIER

Contents lists available at ScienceDirect

Computers in Biology and Medicine

journal homepage: www.elsevier.com/locate/complbiomed

Long short-term memory model – A deep learning approach for medical data with irregularity in cancer predication with tumor markers

Xiaoxing Wu^{a,1}, Hsin-Yao Wang^{b,c,d,1}, Peichang Shi^{b,h}, Rong Sun^e, Xiaolin Wang^e, Zhixiao Luo^e, Fanling Zeng^e, Michael S. Lebowitz^b, Wan-Ying Lin^g, Jang-Jih Lu^{b,c}, Richard Scherer^b, Olivia Price^b, Ziwei Wang^{a,f}, Jiming Zhou^{b,*}, Yonghong Wang^{a,e,*}

- The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China
- 20/20 GeneSystems, Inc, Gaithersburg, MD 20877, USA
- Department of Laboratory Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, 33305, Taiwan
- PhD Program in Biomedical Engineering, Chang Gung University, Taoyuan City, 33301, Taiwan
- Health Management Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China
- Syu Kang Sport Clinic, Taipei, 11217, Taiwan
- University of Maryland, Baltimore County, MD, 20723, USA

(12) United States Patent Cohen et al.

(54) METHODS AND MACHINE LEARNING SYSTEMS FOR PREDICTING THE LIKELIHOOD OR RISK OF HAVING CANCER

(71) Applicant: 20/20 GeneSystems Inc., Rockville, MD (US)
 inventors: Jonathan Cohen, Rockville, MD (US); Jodd Readick, New York, NY (US); Victoria Doseeva, Rockville, MD (US); Peichang Shi, Rockville, MD (US); Jose Miguel Flores-Fernandez, Edmonton (CA)

ssigne: 20/20 GeneSystems, Gaithersburg, MD (US)

otice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 350 days.

ppl. No.: 15/617,899

led: Jun. 8, 2017

Prior Publication Data

S 2018/0068083 A1 Mar. 8, 2018

Related U.S. Application Data

ntinuation-in-part of application No. PCT/US2015/064344, filed on Dec. 7, 2015. (Continued)

(51) Int. Cl. G16H 50/30 (2018.01) G16B 40/00 (2019.01) (Continued)

(52) U.S. Cl. CPC G16H 50/30 (2018.01); G16B 40/00 (2019.02); G16B 40/20 (2019.02); G16B 40/30 (2019.02); (Continued)

(10) Patent No.: US 11,621,080 B2
 (45) Date of Patent: Apr. 4, 2023

(58) Field of Classification Search CPC G06N 20/00; G16H 40/67; G16H 50/50; G16H 10/60; G16H 50/70; G16H 50/20; A61B 5/7264; G16B 40/00 (Continued)

(56) References Cited

U.S. PATENT DOCUMENTS

5,188,934 A 2/1993 Menchen et al.
 5,366,860 A 11/1994 Bergot et al. (Continued)

FOREIGN PATENT DOCUMENTS

WO 9745539 A1 12/1997
 WO 9921881 A1 5/1999 (Continued)


OTHER PUBLICATIONS

Adami, Hans-Olov; McLaughlin, Joseph; Ekblom, Anders; Berne, Christian; Silverman, Debra; Hacker, David; Persson, Ingemar; "Cancer riskin patients with diabetes mellitus," 1991, Cancer causes & control, vol. 2, p. 307-314 (Year: 1991).* (Continued)

Primary Examiner — Joseph D Burgess
 (74) Attorney, Agent, or Firm — Koren Anderson

(57) ABSTRACT

Embodiments of the present invention relate generally to non-invasive methods and tests that measure biomarkers (e.g., tumor antigens) and collect clinical parameters from patients, and computer-implemented machine learning methods, apparatuses, systems, and computer-readable media for assessing a likelihood that a patient has a disease, relative to a patient population or a cohort population. In one embodiment, a classifier is generated using a machine learning system based on training data from retrospective data and subset of inputs (e.g. at least two biomarkers and at least one clinical parameter), wherein each input has an associated weight and the classifier meets a predetermined (Continued)



A Strong & Growing Patent Estate

20/20 has issued U.S. patents with claims covering:

Machine learning systems to identify **multiple cancers** developed with data from thousands of patient records including the values of two or more tumor antigens such as CEA, AFP, CA125, etc.¹

Methods for administering CT scans to individuals at increased risk for **lung cancer** including the measurement of markers CEA, CA125, or Cyfra, etc.²

Additional patent applications covering new patentable subject matter are in preparation.

License royalty income anticipated beginning in 2026.

1) See e.g., U.S. Patent Nos. [12,051,509](#) and [11,621,080](#) (additional patents pending)

2) See e.g., U.S. Patent Nos. [11,733,249](#) and [10,156,575](#) (additional patents pending)

M&A Strategy

Expect to “bolt-on” or acquire other companies that are vertically or horizontally integrated with 20/20 (e.g., suppliers, distributors, or related products)

Desired Attributes for Acquired Companies

- Health & wellness customer base overlaps with those of 20/20
 - Early Cancer Detection
 - Longevity Testing
 - Healthy Whole Foods that positively impact Biomarker Levels
- \$2 to \$8 million in annualized revenues
- Proven year-over-year growth likely to accelerate with modest cash infusions over time
- Line of sight to profitability
- Shareholders eager for liquidity with limited “exit” options

Structure & Operation of Acquired Companies

- Mostly stock transaction
- Each business to initially operate as a wholly-owned subsidiary (rather than an operating division)
- Equity to flow between subsidiaries based on quarterly financial performance
- Cost sharing and economies of scale to reduce overhead and burn of each subsidiary
 - Marketing
 - AI Development & Deployment
 - Accounting, Audit, & HR
 - Legal and IP Development
 - Government Advocacy

Congress Creates a Pathway for Medicare Reimbursement for Multi-Cancer Tests by 2028

On Feb. 3, 2026, the *Multi-Cancer Early Detection Screening Coverage Act* passed Congress and was signed by the President



- Establishes the first statutory pathway for Medicare coverage of MCED blood tests
- CMS authority to reimburse MCEDs beginning in 2028
- Applies to FDA-approved MCED tests deemed clinically appropriate by CMS
- Initial rollout to older Medicare cohorts, with potential expansion over time

A Major Growth Catalyst for OneTest™ for Cancer

- ~67 million Medicare beneficiaries in the U.S. today
- Should accelerate private payer and Medicare Advantage coverage
- Support MCEDs becoming part of routine preventive care over next 3+ years from employer- self-pay funded
- Reinforces OneTest's positioning as a low-cost, accessible MCED ready for broad reimbursement & adoption

MAHA ELEVATE: A Potential Pathway to Medicare Reimbursement for OneTest for Longevity in ~3 years



Part of the Administration's plan to reform America's health systems to address the chronic disease epidemic

- Dec. 2025 CMS Innovation Center announced a new initiative to provide approximately \$100 million to fund 3-year cooperative agreements for up to 30 proposals that promote health and prevention for over 30 million Medicare beneficiaries.
- Seeking lifestyle medicine interventions — currently not covered by Medicare-- **including those focused on nutrition** and physical activity, that demonstrate the ability to slow or prevent chronic disease.
- Interventions tested in MAHA ELEVATE **will inform future Medicare coverage**
- Seeking to transform the U.S. health care system to proactively addresses the root causes of chronic disease (including diet) rather than reactively addressing symptoms.
- We are building partnerships with the goal of competing for selection into MAHA ELEVATE

Abbott Acquiring Exact Sciences for \$23 Billion

"Abbott Laboratories seeks to revitalize growth and expand its diagnostics portfolio, betting on Exact Sciences' MCED technology and established products like Cologuard despite high acquisition costs."

- **Edmond Ingham**, Lead Analyst at *Haggerston BioHealth*
(via Seeking Alpha)

- **\$23 Billion Deal = ~7x Exact Revenue**
- Exact Launched the CancerGuard MCED in September 2025
- This acquisition validates cancer screening and MCEDs as a **long-term strategic priority** for major med-tech players
- Validates the market for early cancer detection and MCEDs

Recent M&A Activity in our Sector



NHS-Galleri Trial Results: What the Data Shows (Released Feb. 2026) — and *What It Means for 20/20 Biolabs*

(142,000 participants; randomized; 3-year UK NHS study)

Primary endpoint not met: No **statistically significant reduction in combined Stage III–IV cancer diagnoses** compared with standard screening alone (but Stage IV cancer diagnoses were substantially reduced)

Clinical & Peer-Reviewed Evidence

- Independent studies and systematic reviews report that **protein-based or multi-analyte MCEs detect a higher proportion of early-stage cancers** than ctDNA-only approaches
- Academic centers (including MD Anderson) have shown **tumor antigen panels outperform ctDNA** for several hard-to-detect cancers
- Real-world and blinded validation studies demonstrate **strong early-stage sensitivity** for protein-based platforms like OneTest

What NHS-Galleri Reinforced

- The NHS-Galleri trial **did not disprove MCEs**, but highlighted the **limitations of ctDNA-dominant tests** in achieving early, population-level impact
- Challenges in early-stage detection are consistent with **ctDNA biology**, not trial execution
- This strengthens interest in **alternative biomarker strategies** designed for earlier disease

Implications for 20/20 Biolabs

- Structural advantage:** Protein-based MCEs are aligned with early-stage cancer biology
- Commercial relevance:** Higher early sensitivity + lower cost supports adoption in employer, occupational, and self-pay markets
- Strategic positioning:** As payers and regulators raise evidentiary standards, platforms optimized for early detection may be favored

Transfer of 20/20 Shares to Brokerage Accounts

- We are working with our stock transfer agent, VStock Transfer, to help facilitate and expedite shareholder transfers.
- U.S. Securities laws limit what a company can publicly disclose by way of a press release before and during the listing process.
- All required SEC filings related to our listing are available at <https://www.sec.gov/>.
- Transferring shares from a transfer agent to a brokerage account takes approximately 3 to 5 business days, in most cases.
- Convertible notes automatically convert into common stock five trading days following the listing.

Thank you for your patience and understanding!



Company

Marc Gordon

Investor Relations

301-219-9387

Investors@2020Biolabs.com

Investor Relations

Chris Tyson

Executive Vice President

MZ Group - MZ North

America

949-491-8235

AIDX@mzgroup.us

NASDAQ: AIDX

2020biolabs.com

